SELLAS Life Sciences (SLS) Gross Margin (2012 - 2022)
SELLAS Life Sciences (SLS) posted quarterly Gross Margin of 90.0% for Q1 2022, down 825.0% year-over-year from 12.41% in Q1 2021, and down 5.0% quarter-over-quarter from 94.74% in Q2 2021.
SELLAS Life Sciences (SLS) Gross Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Gross Margin for 7 consecutive years, with 90.0% the latest figure, recorded in Q1 2022.
- In Q1 2022, Gross Margin fell 825.0% year-over-year to 90.0%; the TTM figure through Dec 2022 stood at 90.0% (down 737.0% YoY), while the FY2022 annual figure was 90.0%, down 737.0% from the prior year.
- Gross Margin retreated to 90.0% in Q1 2022 per SLS's latest filing, from 94.74% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q4 2020 and bottomed at 90.0% in Q1 2022.
- Historically, Gross Margin has averaged 95.75% across 3 years, with a median of 96.49% in 2021.
- On a YoY basis, Gross Margin climbed as much as 825 bps in 2022 and fell as far as 825 bps in 2022.
- SELLAS Life Sciences' Gross Margin stood at 100.0% in 2020, then declined by 5 bps to 94.74% in 2021, then declined by 5 bps to 90.0% in 2022.
- Business Quant data shows SLS's Gross Margin at 90.0% in Q1 2022, 94.74% in Q2 2021, and 98.25% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 90.00% |
| Jun 30, 2021 | 94.74% |
| Mar 31, 2021 | 98.25% |
| Dec 31, 2020 | 100.00% |
| Jun 30, 2015 | 86.16% |
| Mar 31, 2015 | 85.71% |
| Dec 31, 2014 | 85.04% |
| Sep 30, 2014 | 84.75% |
| Jun 30, 2014 | 85.11% |
| Mar 31, 2014 | 84.77% |
| Dec 31, 2013 | 91.80% |
| Sep 30, 2013 | 53.64% |
| Jun 30, 2013 | 100.00% |
| Mar 31, 2013 | 100.00% |
| Dec 31, 2012 | 100.00% |